KR102676822B1 - Atr 키나아제의 헤테로시클릭 저해제 - Google Patents

Atr 키나아제의 헤테로시클릭 저해제 Download PDF

Info

Publication number
KR102676822B1
KR102676822B1 KR1020207004080A KR20207004080A KR102676822B1 KR 102676822 B1 KR102676822 B1 KR 102676822B1 KR 1020207004080 A KR1020207004080 A KR 1020207004080A KR 20207004080 A KR20207004080 A KR 20207004080A KR 102676822 B1 KR102676822 B1 KR 102676822B1
Authority
KR
South Korea
Prior art keywords
alkyl
compound
cycloalkyl
salt
haloalkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020207004080A
Other languages
English (en)
Korean (ko)
Other versions
KR20200028441A (ko
Inventor
프란체스코 마리아 에밀리아 디
필립 존스
크리스토퍼 로렌스 캐롤
제이슨 브라이언트 크로스
수얌부 케사바 비자얀 라마스와미
마이클 개럿 존슨
사라 라이블리
데이비드 라포인트
Original Assignee
더 보드 오브 리젠츠 오브 더 유니버시티 오브 텍사스 시스템
켐파트너 코포레이션
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 더 보드 오브 리젠츠 오브 더 유니버시티 오브 텍사스 시스템, 켐파트너 코포레이션 filed Critical 더 보드 오브 리젠츠 오브 더 유니버시티 오브 텍사스 시스템
Publication of KR20200028441A publication Critical patent/KR20200028441A/ko
Application granted granted Critical
Publication of KR102676822B1 publication Critical patent/KR102676822B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D411/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms
    • C07D411/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020207004080A 2017-07-13 2018-07-13 Atr 키나아제의 헤테로시클릭 저해제 Active KR102676822B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762531951P 2017-07-13 2017-07-13
US62/531,951 2017-07-13
PCT/US2018/042128 WO2019014618A1 (en) 2017-07-13 2018-07-13 HETEROCYCLIC INHIBITORS OF KINASE ATR

Publications (2)

Publication Number Publication Date
KR20200028441A KR20200028441A (ko) 2020-03-16
KR102676822B1 true KR102676822B1 (ko) 2024-06-19

Family

ID=64998660

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020207004080A Active KR102676822B1 (ko) 2017-07-13 2018-07-13 Atr 키나아제의 헤테로시클릭 저해제

Country Status (24)

Country Link
US (3) US10392376B2 (enExample)
EP (1) EP3651768B1 (enExample)
JP (1) JP7159307B2 (enExample)
KR (1) KR102676822B1 (enExample)
CN (2) CN117466884A (enExample)
AU (1) AU2018301696B8 (enExample)
CA (1) CA3069693A1 (enExample)
DK (1) DK3651768T3 (enExample)
ES (1) ES2974334T3 (enExample)
FI (1) FI3651768T3 (enExample)
HR (1) HRP20240368T1 (enExample)
HU (1) HUE066043T2 (enExample)
IL (1) IL271930B (enExample)
LT (1) LT3651768T (enExample)
MX (1) MX2020000386A (enExample)
NZ (1) NZ761374A (enExample)
PH (1) PH12020500072A1 (enExample)
PL (1) PL3651768T3 (enExample)
PT (1) PT3651768T (enExample)
RS (1) RS65466B1 (enExample)
SI (1) SI3651768T1 (enExample)
SM (1) SMT202400106T1 (enExample)
WO (1) WO2019014618A1 (enExample)
ZA (1) ZA202000148B (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018218197A2 (en) 2017-05-26 2018-11-29 Board Of Regents, The University Of Texas System Tetrahydropyrido[4,3-d]pyrimidine inhibitors of atr kinase
US10377591B2 (en) 2017-07-07 2019-08-13 Zebra Technologies Corporation Input handling for media processing devices
SI3651768T1 (sl) 2017-07-13 2024-05-31 Chempartner Corporation Heterociklični inhibitorji atr kinaze
WO2019036641A1 (en) 2017-08-17 2019-02-21 Board Of Regents, The University Of Texas System HETEROCYCLIC INHIBITORS OF KINASE ATR
JP7235338B2 (ja) * 2017-09-08 2023-03-08 ニューウェーブ・ファーマスーティカル・インコーポレイテッド Ａｔｒ阻害剤としての置換ピロロピリジン
WO2019178590A1 (en) 2018-03-16 2019-09-19 Board Of Regents, The University Of Texas System Heterocyclic inhibitors of atr kinase
JP2022503932A (ja) * 2018-09-27 2022-01-12 フォチョン・ファーマシューティカルズ・リミテッド Ｒｅｔキナーゼ阻害剤としての置換イミダゾ［１，２－ａ］ピリジン及び［１，２，４］トリアゾロ［１，５－ａ］ピリジン化合物
KR102803409B1 (ko) * 2019-06-06 2025-05-07 베이징 타이드 파마슈티컬 코퍼레이션 리미티드 Atr 키나제 억제제로서의 2,4,6-삼치환된 피리미딘 화합물
CN113121524B (zh) * 2019-12-31 2023-04-25 南京创济生物医药有限公司 杂环亚砜亚胺化合物及其中间体、制备方法和应用
AU2021282122B2 (en) * 2020-05-29 2023-09-21 Wuxi Life Fountain Biotech Co., Ltd Fluoropyrrolopyridine compound and application thereof
KR20230035070A (ko) * 2020-07-03 2023-03-10 안텐진 디스커버리 리미티드 Atr 억제제 및 이의 용도
CN116848113A (zh) * 2021-02-10 2023-10-03 南京再明医药有限公司 作为hpk1抑制剂的双环类化合物及其应用
MX2023013194A (es) * 2021-05-12 2023-11-15 Chia Tai Tianqing Pharmaceutical Group Co Ltd Compuesto inhibidor de atr que contiene sulfoximina.
WO2022262143A1 (zh) * 2021-06-17 2022-12-22 杭州中美华东制药有限公司 一种吡啶硼酸酯的制备方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007080382A1 (en) 2006-01-11 2007-07-19 Astrazeneca Ab Morpholino pyrimidine derivatives and their use in therapy
US20160287604A1 (en) 2014-08-04 2016-10-06 Bayer Pharma Aktiengesellschaft 2-(morpholin-4-yl)-1,7-naphthyridines

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2001265871A1 (en) * 2000-04-25 2001-11-07 Actelion Pharmaceuticals Ltd Substituted sulfonylaminopyrimidines
MX2009002046A (es) 2006-08-24 2009-03-06 Astrazeneca Ab Derivados de morfolino pirimidina utiles en el tratamiento de trastornos proliferativos.
WO2008032072A1 (en) 2006-09-14 2008-03-20 Astrazeneca Ab 2-benzimidaz0lyl-6-m0rph0lin0-4-piperidin-4-ylpyrimidine derivatives as pi3k and mtor inhibitors for the treatment of proliferative disorders
WO2008125833A1 (en) 2007-04-12 2008-10-23 Piramed Limited Pharmaceutical compounds
US20080292588A1 (en) 2007-05-17 2008-11-27 Anadys Pharmaceuticals, Inc. 1-methyl-benzo[1,2,4]thiadiazine 1-oxide derivatives
KR20100042643A (ko) 2007-07-09 2010-04-26 아스트라제네카 아베 증식성 질환을 치료하기 위한 삼중치환된 피리미딘 유도체
AU2008273889B2 (en) 2007-07-09 2012-03-08 Astrazeneca Ab Trisubstituted pyrimidine derivatives for the treatment of proliferative diseases
CN101809002B (zh) 2007-07-09 2013-03-27 阿斯利康(瑞典)有限公司 用于与mtor激酶和/或pi3k相关的疾病中的吗啉代嘧啶衍生物
AU2009220605A1 (en) 2008-03-06 2009-09-11 Msd K.K. Alkylaminopyridine derivative
WO2010003133A2 (en) 2008-07-03 2010-01-07 Exelixis Inc. Cdk modulators
US20110053923A1 (en) 2008-12-22 2011-03-03 Astrazeneca Chemical compounds 610
WO2010120996A1 (en) 2009-04-17 2010-10-21 Wyeth Llc 5,6,7,8-tetrahydropyrido[3,4-d]pyrimidine compounds, their use as mtor kinase and pi3 kinase inhibitors, and their syntheses
JP2013032290A (ja) 2009-11-20 2013-02-14 Dainippon Sumitomo Pharma Co Ltd 新規縮合ピリミジン誘導体
WO2011106276A1 (en) 2010-02-25 2011-09-01 Merck Sharp & Dohme Corp. Task channel antagonists
WO2011103715A1 (en) 2010-02-25 2011-09-01 Merck Sharp & Dohme Corp. Task channel antagonists
US9249129B2 (en) 2010-03-04 2016-02-02 Cellzome Limited Morpholino substituted urea derivatives as mTOR inhibitors
WO2011143419A1 (en) 2010-05-12 2011-11-17 Vertex Pharmaceuticals Incorporated Pyrazines useful as inhibitors of atr kinase
SA111320519B1 (ar) 2010-06-11 2014-07-02 Astrazeneca Ab مركبات بيريميدينيل للاستخدام كمثبطات atr
UA112517C2 (uk) 2010-07-06 2016-09-26 Новартіс Аг Тетрагідропіридопіримідинові похідні
WO2012147890A1 (ja) 2011-04-27 2012-11-01 持田製薬株式会社 新規アゾール誘導体
SMT202000713T1 (it) 2012-12-07 2021-03-15 Vertex Pharma Pirazolo [1,5-a] pirimidine utili come inibitori dell'atr chinasi per il trattamento di malattie del cancro
LT2986610T (lt) 2013-04-19 2018-04-10 Incyte Holdings Corporation Bicikliniai heterociklai, kaip fgfr inhibitoriai
ES2768678T3 (es) 2013-12-06 2020-06-23 Vertex Pharma Compuesto de 2-amino-6-fluoro-N-[5-fluoro-piridin-3-il]pirazolo[1,5-a]pirimidin-3-carboxamida útil como inhibidor de la ATR quinasa, su preparación, diferentes formas sólidas y derivados radiomarcados de las mismas
JP6487921B2 (ja) 2013-12-17 2019-03-20 ファイザー・インク ＬＲＲＫ２阻害薬としての新規の３，４−二置換−１Ｈ−ピロロ［２，３−ｂ］ピリジンおよび４，５−二置換−７Ｈ−ピロロ［２，３−ｃ］ピリダジン
SG10201902206QA (en) 2014-06-05 2019-04-29 Vertex Pharma Radiolabelled derivatives of a 2-amino-6-fluoro-n-[5-fluoro-pyridin-3-yl]- pyrazolo[1,5-a]pyrimidin-3-carboxamide compound useful as atr kinase inhibitor, the preparation of said compound and different solid forms thereof
JP6678679B2 (ja) 2014-10-13 2020-04-08 エイトリン ファーマシューティカルズ エルエルシー 毛細血管拡張性運動失調症およびＲａｄ３関連（ＡＴＲ）プロテインキナーゼ阻害剤
US10774064B2 (en) 2016-06-02 2020-09-15 Cadent Therapeutics, Inc. Potassium channel modulators
WO2018218197A2 (en) 2017-05-26 2018-11-29 Board Of Regents, The University Of Texas System Tetrahydropyrido[4,3-d]pyrimidine inhibitors of atr kinase
SI3651768T1 (sl) * 2017-07-13 2024-05-31 Chempartner Corporation Heterociklični inhibitorji atr kinaze
WO2019036641A1 (en) 2017-08-17 2019-02-21 Board Of Regents, The University Of Texas System HETEROCYCLIC INHIBITORS OF KINASE ATR
WO2019178590A1 (en) 2018-03-16 2019-09-19 Board Of Regents, The University Of Texas System Heterocyclic inhibitors of atr kinase

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007080382A1 (en) 2006-01-11 2007-07-19 Astrazeneca Ab Morpholino pyrimidine derivatives and their use in therapy
US20160287604A1 (en) 2014-08-04 2016-10-06 Bayer Pharma Aktiengesellschaft 2-(morpholin-4-yl)-1,7-naphthyridines

Also Published As

Publication number Publication date
US20210047311A1 (en) 2021-02-18
WO2019014618A1 (en) 2019-01-17
IL271930A (en) 2020-02-27
US11434233B2 (en) 2022-09-06
ZA202000148B (en) 2024-08-28
JP2020527174A (ja) 2020-09-03
US20200102296A1 (en) 2020-04-02
US10800769B2 (en) 2020-10-13
CA3069693A1 (en) 2019-01-17
DK3651768T3 (da) 2024-03-18
PH12020500072A1 (en) 2020-11-09
SMT202400106T1 (it) 2024-05-14
CN117466884A (zh) 2024-01-30
US10392376B2 (en) 2019-08-27
EP3651768A4 (en) 2021-04-07
EP3651768B1 (en) 2023-12-20
HRP20240368T1 (hr) 2024-08-30
CN111867590B (zh) 2023-11-17
HUE066043T2 (hu) 2024-07-28
AU2018301696B8 (en) 2023-03-23
EP3651768A1 (en) 2020-05-20
CN111867590A (zh) 2020-10-30
KR20200028441A (ko) 2020-03-16
IL271930B (en) 2022-07-01
US20190016713A1 (en) 2019-01-17
LT3651768T (lt) 2024-04-25
FI3651768T3 (fi) 2024-03-14
MX2020000386A (es) 2020-08-06
PL3651768T3 (pl) 2024-09-02
RS65466B1 (sr) 2024-05-31
AU2018301696A1 (en) 2020-02-27
NZ761374A (en) 2025-10-31
SI3651768T1 (sl) 2024-05-31
PT3651768T (pt) 2024-03-20
JP7159307B2 (ja) 2022-10-24
ES2974334T3 (es) 2024-06-26
AU2018301696A8 (en) 2023-03-23
AU2018301696B2 (en) 2022-10-27

Similar Documents

Publication Publication Date Title
KR102676822B1 (ko) Atr 키나아제의 헤테로시클릭 저해제
JP7290627B2 (ja) Ａｔｒキナーゼの複素環式阻害剤
US10745420B2 (en) Tetrahydropyrido[4,3-d]pyrimidine inhibitors of ATR kinase
JP7341156B2 (ja) Ａｔｒキナーゼの複素環式阻害剤
HK40028148A (en) Heterocyclic inhibitors of atr kinase
HK40028148B (en) Heterocyclic inhibitors of atr kinase

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20200211

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20210705

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20230905

Patent event code: PE09021S01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20240426

Patent event code: PE09021S01D

Comment text: Notification of reason for refusal

Patent event date: 20230905

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20240617

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20240617

End annual number: 3

Start annual number: 1

PG1601 Publication of registration